Stefan Sperl
Geschäftsführer bei KIORA PHARMACEUTICALS, INC.
Profil
Stefan Sperl is the founder of Panoptes Pharma GmbH, which was founded in 2013.
He held the title of Chief Operating Officer at the company.
Currently, he is the Executive Vice President-CMC & Operations at Kiora Pharmaceuticals, Inc. He previously worked as a Project Manager at Nabriva Therapeutics GmbH.
Dr. Sperl obtained a doctorate degree from the Max Planck Institute of Biochemistry.
Aktive Positionen von Stefan Sperl
| Unternehmen | Position | Beginn |
|---|---|---|
| KIORA PHARMACEUTICALS, INC. | Geschäftsführer | - |
Ehemalige bekannte Positionen von Stefan Sperl
| Unternehmen | Position | Ende |
|---|---|---|
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Corporate Officer/Principal | - |
Panoptes Pharma GmbH
 Panoptes Pharma GmbH BiotechnologyHealth Technology Panoptes Pharma GmbH develops molecule drugs to treat eye diseases. The firm focuses on a new treatment for autoimmune uveitis, a disease which is one of the major causes of blindness. The company was founded by Franz Obermayr and Stefan Sperl in July 2013 and is headquartered in Wien, Austria. | Gründer | - |
Ausbildung von Stefan Sperl
| Max Planck Institute of Biochemistry | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KIORA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Panoptes Pharma GmbH
Panoptes Pharma GmbH BiotechnologyHealth Technology Panoptes Pharma GmbH develops molecule drugs to treat eye diseases. The firm focuses on a new treatment for autoimmune uveitis, a disease which is one of the major causes of blindness. The company was founded by Franz Obermayr and Stefan Sperl in July 2013 and is headquartered in Wien, Austria. | Health Technology |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
